3PerngRP, chenY, Ming- Liu J, et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non- sail cell lung cancer in a phase Ⅱ randomized Study. J Clin Oncol, 1997,15:2097.
4Cesano A, Lanes,Ross G et,al.stabilization of disease as an indicator of clinical benefit associated with chemotherapy in nonsmall cell lung cancer patients. International J of Oncol,2000,17 (3) :587 ～ 590.
同被引文献21
1Schiller JH, Harringtan D, Belani CP, et al. Comparison of four chemotheraty regimens for advanced non small cell lung cancer [J ]. N Engl J Med, 2002, 346: 92-8.
2Kelly K, Crowley J, Bunn PA, et al. Randomized phase Ul trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatm in the treatment of patients s with advanced non-small cell lung cancer. A southwest Oncology Group trial [J]. J Clin Oncol, 2001, 19: 3210-18.
3孙燕,周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,2006:497.
4Bellani CP, Lee JS, Socinski MA, et al. Randomized phase Ⅲ trial comparing cisplatin-ctoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer [J]. Ann Oncol, 2005, 16 (7): 1069-75.
5Bookman MA. Topotecan in squamous cell carcinoma of the cervix: A phase Ⅱ study of the gynecologic oncology group [J]. Gynecol Oncol, 2000, 77: 446-9.
6Macdonald JS, Jacobon JL, Steven JK,et al. A phase Ⅱ trial of topotecan in rsophogeal carcinoma. A southwest oncology group study (SWOG 9339)[J]. Invest New Drugs, 2000, 18(2): 199-202.
7Asbury RF, Lipsitz S, Graham D, et al. An Eastern Cooperative Oncology Group Study (E2293) [J ]. Am J Clin Oncol, 2000, 23(11): 45 -6.
8AbeloffMD, Armitage JO, Licher AS, et al. Clinical oncology[M]. Beijing: Science press, 2001: 393.
9AbeloffMD, Armitage JO, Licher AS, et al. Clinical oncology[M]. Beijing: Science Press, 2001: 1262.
10Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer[J]. J Clin Oncol, 1999, 17: 658-67.
